肠道微生态与肿瘤治疗相关消化系统并发症管理中国专家共识

doi:10.3760/cma.j.cn371439-20220911-00140

摘要/Abstract

中国抗癌协会肿瘤与微生态专业委员会. 肠道微生态与肿瘤治疗相关消化系统并发症管理中国专家共识[J]. 国际肿瘤学杂志, 2022, 49(12): 711-717.

参考文献 22

[1]	Hesketh PJ, Kris MG, Basch E, et al. Antiemetics: American Society of Clinical Oncology clinical practice guideline update[J]. J Clin Oncol, 2017, 35(28): 3240-3261. DOI: 10.1200/JCO.2017.74.4789. doi: 10.1200/JCO.2017.74.4789 pmid: 28759346
[2]	国家卫生健康委员会医院管理研究所; 中华医学会肠外肠内营养学分会; 中华医学会肠外肠内营养学分会肠道微生态协作组. 肠道菌群移植临床应用管理中国专家共识(2022版)[J]. 中华胃肠外科杂志, 2022, 25(9): 747-756. DOI: 10.3760/cma.j.cn441530-20220725-00324. doi: 10.3760/cma.j.cn441530-20220725-00324
[3]	中国抗癌协会肿瘤与微生态专业委员会. 肠道微生态与造血干细胞移植相关性中国专家共识[J]. 国际肿瘤学杂志, 2021, 48(3): 129-135. DOI: 10.3760/cma.j.cn371439-20210202-00027. doi: 10.3760/cma.j.cn371439-20210202-00027
[4]	Gupta K, Walton R, Kataria SP. Chemotherapy-induced nausea and vomiting: pathogenesis, recommendations, and new trends[J]. Cancer Treat Res Commun, 2021, 26: 100278. DOI: 10.1016/j.ctarc.2020.100278. doi: 10.1016/j.ctarc.2020.100278
[5]	Razvi Y, Chan S, McFarlane T, et al. ASCO, NCCN, MASCC/ESMO: a comparison of antiemetic guidelines for the treatment of chemotherapy-induced nausea and vomiting in adult patients[J]. Support Care Cancer, 2019, 27(1): 87-95. DOI: 10.1007/s00520-018-4464-y. doi: 10.1007/s00520-018-4464-y pmid: 30284039
[6]	Hong CHL, Gueiros LA, Fulton JS, et al. Systematic review of basic oral care for the management of oral mucositis in cancer patients and clinical practice guidelines[J]. Support Care Cancer, 2019, 27(10): 3949-3967. DOI: 10.1007/s00520-019-04848-4. doi: 10.1007/s00520-019-04848-4 pmid: 31286232
[7]	Bowen JM, Wardill HR. Advances in the understanding and manage-ment of mucositis during stem cell transplantation[J]. Curr Opin Support Palliat Care, 2017, 11(4): 341-346. DOI: 10.1097/SPC.0000000000000310. doi: 10.1097/SPC.0000000000000310
[8]	Ando T, Sakumura M, Mihara H, et al. A review of potential role of capsule endoscopy in the work-up for chemotherapy-induced diarrhea[J]. Healthcare (Basel), 2022, 10(2): 218. DOI: 10.3390/healthcare10020218. doi: 10.3390/healthcare10020218
[9]	Hay T, Bellomo R, Rechnitzer T, et al. Constipation, diarrhea, and prophylactic laxative bowel regimens in the critically ill: a systematic review and meta-analysis[J]. J Crit Care, 2019, 52: 242-250. DOI: 10.1016/j.jcrc.2019.01.004. doi: S0883-9441(18)31259-0 pmid: 30665795
[10]	Agamennone V, Krul CAM, Rijkers G, et al. A practical guide for probiotics applied to the case of antibiotic-associated diarrhea in the Netherlands[J]. BMC Gastroenterol, 2018, 18(1): 103. DOI: 10.1186/s12876-018-0831-x. doi: 10.1186/s12876-018-0831-x pmid: 30078376
[11]	Wang Y, Abu-Sbeih H, Mao E, et al. Immune-checkpoint inhi-bitor-induced diarrhea and colitis in patients with advanced malignancies: retrospective review at MD Anderson[J]. J Immunother Cancer, 2018, 6(1): 37. DOI: 10.1186/s40425-018-0346-6. doi: 10.1186/s40425-018-0346-6
[12]	Taplitz RA, Kennedy EB, Bow EJ, et al. Outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology and infectious diseases society of America clinical practice guideline update[J]. J Clin Oncol, 2018, 36(14): 1443-1453. DOI: 10.1200/JCO.2017.77.6211. doi: 10.1200/JCO.2017.77.6211 pmid: 29461916
[13]	Cooksley T, Font C, Scotte F, et al. Emerging challenges in the evaluation of fever in cancer patients at risk of febrile neutropenia in the era of COVID-19: a MASCC position paper[J]. Support Care Cancer, 2021, 29(2): 1129-1138. DOI: 10.1007/s00520-020-05906-y. doi: 10.1007/s00520-020-05906-y pmid: 33230644
[14]	Kapandji N, Azoulay E, Zafrani L. Recent advances in neutropenic enterocolitis: insights into the role of gut microbiota[J]. Blood Rev, 2022, 54: 100944. DOI: 10.1016/j.blre.2022.100944. doi: 10.1016/j.blre.2022.100944
[15]	Duceau B, Picard M, Pirracchio R, et al. Neutropenic enterocolitis in critically ill patients: spectrum of the disease and risk of invasive fungal disease[J]. Crit Care Med, 2019, 47(5): 668-676. DOI: 10.1097/CCM.0000000000003687. doi: 10.1097/CCM.0000000000003687 pmid: 30741755
[16]	Benedetti E, Bruno B, Martini F, et al. Early diagnosis of neu-tropenic enterocolitis by bedside ultrasound in hematological malignancies: a prospective study[J]. J Clin Med, 2021, 10(18): 4277. DOI: 10.3390/jcm10184277. doi: 10.3390/jcm10184277
[17]	Khanna S. Advances in clostridioides difficile therapeutics[J]. Expert Rev Anti Infect Ther, 2021, 19(9): 1067-1070. DOI: 10.1080/14787210.2021.1874919. doi: 10.1080/14787210.2021.1874919
[18]	Quraishi MN, Widlak M, Bhala N, et al. Systematic review with meta-analysis: the efficacy of faecal microbiota transplantation for the treatment of recurrent and refractory Clostridium difficile infection[J]. Aliment Pharmacol Ther, 2017, 46(5): 479-493. DOI: 10.1111/apt.14201. doi: 10.1111/apt.14201
[19]	Hou K, Wu ZX, Chen XY, et al. Microbiota in health and diseases[J]. Signal Transduct Target Ther, 2022, 7(1): 135. DOI: 10.1038/s41392-022-00974-4. doi: 10.1038/s41392-022-00974-4
[20]	Martin A, Fahrbach K, Zhao Q, et al. Association between carba-penem resistance and mortality among adult, hospitalized patients with serious infections due to Enterobacteriaceae: results of a systematic literature review and meta-analysis[J]. Open Forum Infect Dis, 2018, 5(7): ofy150. DOI: 10.1093/ofid/ofy150. doi: 10.1093/ofid/ofy150
[21]	Cammarota G, Ianiro G, Kelly CR, et al. International consensus conference on stool banking for faecal microbiota transplantation in clinical practice[J]. Gut, 2019, 68(12): 2111-2121. DOI: 10.1136/gutjnl-2019-319548. doi: 10.1136/gutjnl-2019-319548 pmid: 31563878
[22]	Guo Z, Gao HY, Zhang TY, et al. Analysis of allogeneic hemato-poietic stem cell transplantation with high-dose cyclophosphamide-induced immune tolerance for severe aplastic anemia[J]. Int J Hematol, 2016, 104(6): 720-728. DOI: 10.1007/s12185-016-2106-z. doi: 10.1007/s12185-016-2106-z

肠道微生态与肿瘤治疗相关消化系统并发症管理中国专家共识

RichHTML

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 22

相关文章 15

编辑推荐

Metrics

本文评价

[1]	刘娜, 寇介丽, 杨枫, 刘桃桃, 李丹萍, 韩君蕊, 杨立洲. 血清miR-106b-5p、miR-760联合低剂量螺旋CT诊断早期肺癌的临床价值[J]. 国际肿瘤学杂志, 2024, 51(6): 321-325.
[2]	钱晓涛, 石子宜, 胡格, 吴晓维. Ⅲ~ⅣA期食管鳞状细胞癌放化疗后行巩固化疗的疗效：一项真实世界临床研究[J]. 国际肿瘤学杂志, 2024, 51(6): 326-331.
[3]	杨蜜, 别俊, 张加勇, 邓佳秀, 唐组阁, 卢俊. 局部晚期可切除食管癌新辅助治疗疗效及预后分析[J]. 国际肿瘤学杂志, 2024, 51(6): 332-337.
[4]	袁健, 黄燕华. Hp-IgG抗体联合血清DKK1、sB7-H3对早期胃癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(6): 338-343.
[5]	陈红健, 张素青. 血清miR-24-3p、H2AFX与肝癌患者临床病理特征及术后复发的关系研究[J]. 国际肿瘤学杂志, 2024, 51(6): 344-349.
[6]	郭泽浩, 张俊旺. PFDN及其亚基在肿瘤发生发展中的作用[J]. 国际肿瘤学杂志, 2024, 51(6): 350-353.
[7]	张百红, 岳红云. 新作用机制的抗肿瘤药物进展[J]. 国际肿瘤学杂志, 2024, 51(6): 354-358.
[8]	许凤琳, 吴刚. EBV在鼻咽癌肿瘤免疫微环境和免疫治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 359-363.
[9]	王盈, 刘楠, 郭兵. 抗体药物偶联物在转移性乳腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 364-369.
[10]	张蕊, 褚衍六. 基于FIT与肠道菌群的结直肠癌风险评估模型的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 370-375.
[11]	高凡, 王萍, 杜超, 褚衍六. 肠道菌群与结直肠癌非手术治疗的相关研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 376-381.
[12]	王丽, 刘志华, 杨伟洪, 蒋凤莲, 李全泳, 宋浩杰, 鞠文东. ROS1突变肺腺鳞癌合并脑梗死为主要表现的Trousseau综合征1例[J]. 国际肿瘤学杂志, 2024, 51(6): 382-384.
[13]	刘静, 刘芹, 黄梅. 基于SMOTE算法的食管癌放化疗患者肺部感染的预后模型构建[J]. 国际肿瘤学杂志, 2024, 51(5): 267-273.
[14]	杨琳, 路宁, 温华, 张明鑫, 朱琳. 炎症负荷指数与胃癌临床关系研究[J]. 国际肿瘤学杂志, 2024, 51(5): 274-279.
[15]	王俊毅, 洪楷彬, 纪荣佳, 陈大朝. 癌结节对结直肠癌根治性切除术后肝转移的影响[J]. 国际肿瘤学杂志, 2024, 51(5): 280-285.